Wee1
Phase 1b dose-escalation study of ZN-c3, a Wee1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian, peritoneal, or fallopian tube cancer
Fu, S. et al. (2021) European Society for Medical OncologyPharmacodynamic evidence for Wee1 target engagement in surrogate and tumor tissues from a Phase 1 study of the Wee1 inhibitor ZN-c3
Chalasani, P. et al. (2021) European Society for Medical OncologyDiscovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer
Huang, P. et al. (2021) J. Med. Chem.Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Lheureux, S. et al. (2021) The Lancet JournalA phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma
Liu, J.F. et al. (2020) Society of Gynecologic OncologySequential Therapy with PARP and Wee1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Fang, Y. et al. (2019) Cancer CellDose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination with Gemcitabine and Radiation for Patients with Locally Advanced Pancreatic Cancer
Cuneo, K. C. et al. (2019) J of Clinical OncologyPhase II Study of Wee1 Inhibitor AZD1775 plus Carboplatin in Patients with TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Leijen, S. et al. (2016) J of Clinical Oncology
BCL-2
A Phase 1 dose-escalation study of ZN-d5, a BCL-2 inhibitor with improved selectivity, in subjects with advanced non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML)
Zaucha, J. et al. (2021) European Society for Medical OncologyDiscovery of ZN-d5, a potent BCL-2 inhibitor with improved selectivity for BCL-2
Pinchman, J. et al. (2021) European Society for Medical OncologyA Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer
Lok, S. W. et al. (2019) Cancer Discovery
SERD
ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer
Kalinsky, K. et al. (2021) SABCSA Phase 1/2 dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2– breast cancer
Abramson, V. et al. (2021) European Society for Medical OncologyA Phase 1b dose-escalation study of ZN-c5, an oral selective estrogen receptor degrader (SERD), in combination with abemaciclib in patients with advanced estrogen receptor (ER)+/HER2– breast cancer
Keogh, G. P. et al. (2021) European Society for Medical OncologyDiscovery of ZN-c5, a novel potent and oral selective estrogen receptor degrader
Samatar, A. A., et al. (2020) AACR Virtual Annual Meeting IISelective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Patel, H. K., Bihani, T. (2018) Pharmacology & TherapeuticsPharmacokinetic and pharmacodynamic analysis of Fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
Wardell, S. E. et al. (2019) Breast Cancer Res TreatFinal overall survival: Fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial
Di Leo, A. et al. (2014) J Natl Cancer Inst.Buparlisib plus Fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Leo, A. D. et al. (2018) The Lancet Oncology
EGFR
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer: NEJM
Jänne, P. A. et al. (2015) New England J of Medicine